HDAX Therapeutics Analysis: $5M Raised
What is HDAX Therapeutics?
HDAX Therapeutics develops small molecules that use a novel 2-site binding mechanism to target HDAC6, a protein linked to neuropathies and cardiovascular diseases. The technology improves drug selectivity, efficacy, and safety profiles compared to existing treatments. The company is focused on advancing therapies for diseases with poor treatment standards.
Location
Mississauga, Canada
Employees
11-50
Founded
2021
Funding Status
Seed
Other Considerations
None available
Product Features & Capabilities
- 2-site HDAC6 binding small molecules
- Targeted therapy for neuropathies and cardiovascular diseases
- Enhanced drug selectivity and safety profile
Use Cases
Develop small molecules to treat HDAC6-related neuropathies; Design therapies for cardiovascular diseases with poor treatment standards; Improve targeting of HDAC6 to enhance drug efficacy; Advance differentiated small molecules for neurology indications; Create safer, more selective treatments for cytoskeleton-related disorders
See something that needs updating? Suggest edits to this profile.